Skip to main content
Fig. 3 | Acta Neuropathologica Communications

Fig. 3

From: Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis

Fig. 3

Reduction of efnA5 levels in SOD1G93A mice is detrimental and shortens survival and disease duration. Disease progression was closely monitored in a-f SOD1G93A EfnA5+/+ and SOD1G93A EfnA5+/− mice from the age of 60 days onwards (N = 26–28). a Weight and b and c motor performance decline over time on b the hanging wire (HW) and c rotarod tests is shown. Data is represented as mean ± SEM and two-way ANOVA test with repeated measurements was used to determine differences among genotypes. d Disease onset differences were compared between the two genotypes with the Log-rank test whereas e survival was analysed with the two-tailed Mann-Whitney test for non-parametric data: * P < 0.05. f Disease duration was analysed with a two-tailed student t-test: * P < 0.05. g EfnA5 expression levels in the lumbar spinal cord of end-stage mice were determined by qPCR and data is represented as mean ± SEM (N = 7–9). Different genotypes were compared with a one-way ANOVA with Tukey’s multiple comparisons test: *** P < 0.001

Back to article page